Haptoglobin 2-2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy

Br J Biomed Sci. 2014;71(2):79-81. doi: 10.1080/09674845.2014.11669969.
No abstract available

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cross-Sectional Studies
  • Erythropoietin / therapeutic use
  • Female
  • Genotype
  • Haptoglobins / genetics*
  • Humans
  • Iron / blood*
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / drug therapy
  • Kidney Failure, Chronic / genetics*
  • Male
  • Middle Aged
  • Phenotype
  • Recombinant Proteins / therapeutic use
  • Treatment Failure

Substances

  • EPO protein, human
  • HP protein, human
  • Haptoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Iron